Dr. Benjamin Musher to Chair Phase 1-2 Study Evaluating XBiotech’s Natrunix™ Anti-Cancer Therapy in Pancreatic Cancer
AUSTIN, Texas, Sept. 08, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) today announced that Benjamin Musher M.D., will chair XBiotech’s clinical program for pancreatic cancer. The Company is developing a novel cancer drug, Natrunix™, to be used in combination with cytotoxic anti-cancer agents. Natrunix™ specifically blocks a substance that has been shown to stimulate tumor blood supply and break down connective tissue, which can support tumor growth and destruction of healthy tissue. The anti-inflammatory activity of Natrunix™ is also being evaluated for its ability to reduce the toxicity and injury caused by the cytotoxic anti-cancer agents themselves.
XBiotech’s pancreatic cancer program, 1-BETTER, launched with a randomized, double-blind, placebo-controlled Phase 1-2 study, allows the Company to evaluate dose levels, drug interaction and anti-cancer activity for Natrunix™. Dr. Musher is Medical Director of Medical Oncology at Dan L. Duncan Comprehensive Cancer Center and Associate Professor at Baylor College of Medicine. Dr. Musher is a member of the American Society of Clinical Oncology and has authored numerous peer-reviewed articles in oncology, including treatments for pancreatic cancer. In addition to Natrunix™, Dr. Musher has investigated cutting-edge pancreatic cancer therapies, including the use of tumor-targeting viruses. He has also researched and published on clinical practices relating to the treatment of pancreatic cancer, to better understand the decision-making processes and challenges faced by oncologists in the treatment of this extremely challenging form of cancer.
As chair of the 1-BETTER pancreatic cancer program, Dr. Musher will lead the clinical program and personally treat pancreatic cancer patients at the Dan L. Duncan Comprehensive Cancer Center, at St. Luke’s Hospital in Houston, Texas. Dr. Musher stated, “Pancreatic cancer is a devastating disease and remains the third leading cause of cancer-related death in the United States. Most patients with metastatic pancreatic cancer are eligible for only cytotoxic chemotherapy, which generally yields short-lived responses and can cause significant toxicity. More effective and rationally designed therapies are therefore desperately needed. By targeting cancer-related inflammation, Natrunix™ may facilitate better control of tumor growth, reduce toxicity from chemotherapy, and improve well-being of patients with advanced pancreatic cancer.”
Dr. Musher will oversee the 1-BETTER study that will involve at least 20 other leading cancer centers around the country. The study will evaluate Natrunix™ in combination with ONIVYDE and 5-fluorouracil and generate preliminary data on overall survival, progression-free survival, time-to-treatment failure, and objective response rates. Numerous quality-of-life measures will also be explored, hopefully showing a reduction in chemotherapy-related toxicity.
John Simard, President and CEO of XBiotech commented, “We are honored to have Dr. Musher chair this study for which we are eagerly anticipating results.”
About True Human™ Therapeutic Antibodies
XBiotech’s True Human™ antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech’s True Human™ antibodies have the potential to harness the body’s natural immunity to fight disease with increased safety, efficacy and tolerability.
XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human™ proprietary technology. XBiotech currently is advancing a robust pipeline of antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech is also leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce therapies urgently needed by patients worldwide. For more information, visit www.xbiotech.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Fobi Data Exchange Launches With First Partner, In-Touch Group, A Leading UK Platform Managing Data From 6,000 Independent Convenience Stores22.9.2021 12:00:00 CEST | Press release
In-Touch group will optimize Data With Fobi AI Driven Analytics And Monetize Through Global CPG Brands. Fobi Data Exchange (FDX) Delivers Analytics For Both Convenience Stores and CPG Brands Previously Thought Unattainable VANCOUVER, British Columbia, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Fobi AI Inc. (FOBI: TSXV FOBIF: OTCQB) (the “Company” or “FOBI”), a global leader in providing real-time data analytics through artificial intelligence to drive operational efficiencies and profitability, is pleased to announce the launch of the Fobi Data Exchange (“FDX”) with its first data monetization agreement and partner, In-Touch Group, a provider of consumer insights and digital marketing to retailers and consumers. In-Touch currently manages a data lake of point-of-sale transactions for approximately 6,000 convenience stores, which is projected to increase to approximately 10,000 stores by the end of 2021. Through FDX, Fobi will optimize and monetize this data by providing Global CPG brands with
RESULT OF RIKSBANK REVERSED AUCTIONS TREASURY BILLS22.9.2021 11:07:00 CEST | Press release
Auction date2021-09-22 LoanDEC 2021IsinSE0015244405Coupon, %0.00Maturity2021-12-15 Tendered volume, SEK mln1,000 +/- 500Offered volume, SEK mln2,800 Volume bought, SEK mln1,000 Number of bids11 Number of accepted bids10 Average yield, %-0.238 %Lowest accepted yield, %-0.288 %Highest yield, %-0.205 %Accepted at lowest yield, %20.00 Auction date2021-09-22 LoanJUN 2022IsinSE0016102057Coupon, %0.00Maturity2022-06-15Tendered volume, SEK mln1,000 +/- 500Offered volume, SEK mln2,000 Volume bought, SEK mln1,000 Number of bids6 Number of accepted bids1 Average yield, %-0.288 %Lowest accepted yield, %-0.288 %Highest yield, %-0.288 %Accepted at lowest yield, %100.00 Auction date2021-09-22 LoanSEP 2022IsinSE0016787204Coupon, %0.00Maturity2022-09-21Tendered volume, SEK mln500 +/- 250Offered volume, SEK mln1,000 Volume bought, SEK mln500 Number of bids3 Number of accepted bids1 Average yield, %-0.311 %Lowest accepted yield, %-0.311 %Highest yield, %-0.311 %Accepted at lowest yield, %100.00
Result of Riksbank´s purchases of Commercial Paper22.9.2021 10:00:00 CEST | Press release
AuctionAuction resultsAuction date2021-09-22Settlement date2021-09-24Credit rating class1Term3mFixed purchase rate, %0.3Total bid amount, SEK mln0Accepted volume, SEK mln0Percentage alloted, %0Number of bids0 AuctionAuction resultsAuction date2021-09-22Settlement date2021-09-24Credit rating class1Term6mFixed purchase rate, %0.4Total bid amount, SEK mln0Accepted volume, SEK mln0Percentage alloted, %0Number of bids0 AuctionAuction resultsAuction date2021-09-22Settlement date2021-09-24Credit rating class2Term3mFixed purchase rate, %0.6Total bid amount, SEK mln0Accepted volume, SEK mln0Percentage alloted, %0Number of bids0 AuctionAuction resultsAuction date2021-09-22Settlement date2021-09-24Credit rating class2Term6mFixed purchase rate, %0.7Total bid amount, SEK mln0Accepted volume, SEK mln0Percentage alloted, %0Number of bids0
Pairing fintech with online marketplaces creates outsized returns, according to new Adevinta report22.9.2021 09:23:03 CEST | Press release
European marketplaces are now worth a combined €685B Fintech-enabled marketplaces have EV/Sales of 6.7x, compared to 5.3x and 4.6x for other marketplaces and financial services, respectively Record investment in online marketplaces (€78B in 2021YTD) means that marketplaces have significant dry powder available to invest Online marketplaces sales now account for 19.5% of all consumer spending, compared to 13.6% in 2019 Barcelona and London, 22 September 2021: As consumer spending continues to shift rapidly online, online marketplaces are increasingly integrating fintech solutions to make it easier for consumers to complete purchases online, and also developing new revenue streams, according to a new Adevinta report on fintech-enabled marketplaces in partnership with DealRoom and Speedinvest. Data from our Fintech-enabled Marketplaces report, the second in a series of reports on marketplaces trends, shows that pairing financial services with online marketplaces creates outsized returns,
JDE Peet’s successfully prices inaugural USD 1.75 billion multi-tranche bond issue22.9.2021 08:00:00 CEST | Press release
PRESS RELEASE Amsterdam, 22 September 2021 Key highlights Debut bond offering on the USD debt capital marketsUSD 1.75 billion priced across three tranches in the investment grade bond market with a weighted average coupon of 1.46% and a weighted average tenor of 6.0 years The proceeds will be used to refinance existing debt facilities at attractive interest rates and further balances the maturity profile JDE Peet’s (EURONEXT: JDEP), the world’s leading pure-play coffee and tea company by revenue, today announced that it has priced USD 1.75 billion aggregate principal of bonds (the “Notes”). The Notes will be issued on 24 September 2021 and comprise the following series: 3.0-year USD 500 million 0.800% Notes due 20245.3-year USD 750 million 1.375% Notes due 202710-year USD 500 million 2.250% Notes due 2031 The financing package has a weighted average coupon of 1.46% and weighted average maturity of 6.0 years. The net proceeds of the Notes will be used to repay outstanding indebtedness,
Sinch tar ledande position inom interaktiva meddelandetjänster genom förvärv av MessengerPeople22.9.2021 07:30:00 CEST | Pressemelding
Stockholm, Sverige – 22 september 2021 – Sinch AB (publ), en ledande global leverantör av molntjänster för kundinteraktion via mobilen, meddelade idag att man har ingått ett bindande avtal om att förvärva MessengerPeople, en ledande tysk leverantör av mjukvara för kundkommunikation genom meddelandetjänster. Köpeskillingen uppgår till 48 miljoner EUR på kassa- och skuldfri basis, varav Sinch betalar 33,6 miljoner EUR kontant och 14,4 miljoner EUR i form av nya aktier i Sinch. Med gårdagens valutakurs där EUR/SEK är 10,18 motsvarar detta en sammanlagd köpeskilling om 489 miljoner SEK. MessengerPeople grundades i München 2015 och erbjuder en molnbaserad mjukvara som gör det enkelt för företag att kommunicera med sina kunder via interaktiva meddelandetjänster som WhatsApp, Telegram och Apple Business Chat (iMessage). MessengerPeople insåg tidigt potentialen i nästa generations meddelandetjänster och har utvecklat innovativa mjukvaruverktyg som gör att företag kan dra nytta av dessa möjligh
Fiberklaar selects Solutions 30 as key partner to provide fiber-to-the-home (FTTH) broadband in Flanders (Belgium)22.9.2021 07:30:00 CEST | Press release
Signature of a 3-year extendable master agreement covering 60,000 homes passed per year Fiberklaar, a fiber network company that was founded in 2021 by EQT Infrastructure and Proximus to design, build and maintain a Fiber-to-the-Home (“FTTH”) network that is open and accessible to all operators in Flanders, has selected Solutions 30 as one of its key partners. Over the next seven years, Fiberklaar has the ambition to connect 1.5 million houses to ultra-high speed Internet and to build 300,000 connections in the coming two years. In its process to select the long-term partners that will help build the largest broadband network in Flanders, Fiberklaar has selected Solutions 30 and has entrusted the Company with passing up to 60,000 homes per year. Both companies have signed a master agreement that will be effective starting on 21 September 2021. Commenting on this agreement, Rik Missault, CEO of Fiberklaar said "We are very pleased to call Solutions 30 one of our key partners in our ambi